Colon cancer's 'invisibility cloak' cracked: Gene switch leads to 100% tumor remission in mice

Canadian researchers have uncovered a potential key to enhancing cancer immunotherapy. A study from the University of Calgary, published in Cell Reports Medicine, identified a mechanism by which some colon cancer cells evade the immune system.

These cancer cells produce a protein known as NOTUM. This protein effectively shields the tumor, creating an "invisibility cloak" that prevents immune cells from detecting the threat. This evasion is a significant reason why many colon cancer patients do not respond well to existing immunotherapies, with only about 15% seeing notable benefits.

The research team utilized gene-editing technology to switch off the gene responsible for NOTUM production in colon cancer cells. Once this "cloak" was removed, the cancer cells became visible to the immune system. In experiments with mice, tumors began to shrink even without immunotherapy. When combined with immunotherapy, the tumors in the mouse models experienced a complete 100% remission.

While these results are currently limited to animal studies, the discovery of NOTUM as a potential "off switch" for immune resistance in colon cancer offers a promising new avenue. Researchers are hopeful that similar "invisibility cloak" mechanisms might exist in other solid tumors, such as pancreatic and lung cancers, potentially paving the way for broader improvements in cancer treatment.

“

This mechanism is like giving cancer cells an invisibility cloak, making immune cells think that everything is normal in the surrounding tissue and letting the cancer cells go.